ESCMID

Final Programme

European Congress of
Clinical Microbiology
and Infectious Diseases

Madrid, Spain
21 – 24 April 2018

ECCMID





28th

www.eccmid.org

Committees

ESCMID Executive Committee



Mario Poljak
ESCMID President
Ljubljana, Slovenia



Jesús Rodríguez-Baño
ESCMID President-elect &
Secretary General
Seville, Spain



Murat Akova
Past-President and
Communications & Publications Officer
Ankara, Turkey



Alexander W. Friedrich
Treasurer
Groningen, Netherlands



Maurizio Sanguinetti
Professional Affairs Officer
Rome, Italy



Evelina Tacconelli
Education Officer
Tübingen, Germany



Annelies Zinkernagel
Scientific Affairs Officer
Zurich, Switzerland

ESCMID Ad-hoc Executive Committee Members



Winfried V. Kern
ECCMID Programme Director
Freiburg, Germany



Leonard Leibovici
CMI Editor-in-Chief
Petah-Tiqva, Israel



Luigia Scudeller
ESCMID Guidelines Director
Pavia, Italy



Christian G. Giske
EUCAST Chairperson
Stockholm, Sweden

Committees

ECCMID Programme Committee (EPC)

Winfried V. Kern, Freiburg, Germany, *ECCMID Programme Director*
Murat Akova, Ankara, Turkey
Sevtap Arikan-Akdagli, Ankara, Turkey
Robert Bonomo, Cleveland, OH, United States
Thierry Calandra, Lausanne, Switzerland
Jordi Carratala, Barcelona, Spain
Francesco Castelli, Brescia, Italy
Jon Friedland, London, United Kingdom
Alexander Friedrich, Groningen, Netherlands
Ana Gales, São Paulo, Brazil
Carolina Garcia Vidal, Barcelona, Spain
Christian Giske, Stockholm, Sweden
Mary Horgan, Cork, Ireland
Po-Ren Hsueh, Taipei, Taiwan
Jan Kluytmans, Breda, Netherlands
Dimitrios Kontoyiannis, Houston, TX, United States
Jaime Labarca, Santiago, Chile
Frédéric Laurent, Lyon, France
Amel Letaief, Sousse, Tunisia
Rogelio López-Velez, Madrid, Spain
Kristine Morch, Bergen, Norway
Marc Nicol, Cape Town, South Africa
Elisabet Nielsen, Uppsala, Sweden
Hanna Nohynek, Helsinki, Finland
Eli Perencevich, Iowa City, IA, United States
Mario Poljak, Ljubljana, Slovenia
Elisabeth Puchhammer, Vienna, Austria
Camilla Rodrigues, Mumbai, India
Jesús Rodriguez-Baño, Seville, Spain
Holger Rohde, Hamburg, Germany
Maurizio Sanguinetti, Rome, Italy
Katja Seme, Ljubljana, Slovenia
Mark Shirtliff, Baltimore, MD, United States
Maria Souli, Athens, Greece
Arnfinn Sundsfjord, Troms, Norway
Yupin Suputtamongkol, Bangkok, Thailand
Evelina Tacconelli, Tübingen, Germany
Arjana Tambic, Zagreb, Croatia
Kate Templeton, Edinburgh, United Kingdom
Jean-François Timsit, Paris, France
Françoise van Bambeke, Brussels, Belgium
Linos Vandekerckhove, Ghent, Belgium
Annelies Zinkernagel, Zurich, Switzerland

ESCMID Education Subcommittee (ES)

Evelina Tacconelli, Tübingen, Germany, *Chairperson*
Esmita Charani, London, United Kingdom
Cansu Çimen, Istanbul, Turkey, *Ad-hoc*
Giovanni Delogu, Rome, Italy
Önder Ergönül, Istanbul, Turkey
Laurent Poirel, Fribourg, Switzerland
Kaisu Hellevi Rantakokko-Jalava, Turku, Finland
Katja Seme, Ljubljana, Slovenia
Agnes Maria Sonnevend, Al Ain, United Arab Emirates
Maria Souli, Athens, Greece
Thea-Christin Zapf, Marburg, Germany, *Ad-hoc*
Snjezana Zidovec Lepej, Zagreb, Croatia

ESCMID Publication Subcommittee (PS)

Murat Akova, Ankara, Turkey, *Chairperson*
Emma Bruun, Oxford, United Kingdom
Leonard Leibovici, Petah-Tiqva, Israel
Fiona Macnab, London, United Kingdom
Mario Poljak, Ljubljana, Slovenia

ESCMID Scientific Affairs Subcommittee (SAS)

Annelies Zinkernagel, Zurich, Switzerland, *Chairperson*
Oliver James Dyar, Stockholm, Sweden
Carolina Garcia Vidal, Barcelona, Spain
Luigi Gradoni, Rome, Italy
Gilbert Greub, Lausanne, Switzerland
Andreas H. Groll, Münster, Germany
Mona Johannessen, Troms, Norway
Souha S. Kanj, Beirut, Lebanon
Frédéric Laurent, Lyon, France
Adriana Vince, Zagreb, Croatia

ESCMID Professional Affairs Subcommittee (PAS)

Maurizio Sanguinetti, Rome, Italy, *Chairperson*
Emmi Andersson, Stockholm, Sweden
Nur Benzonana, Istanbul, Turkey
Julia Anna Bielicki, London, United Kingdom
Elena Carrara, Tübingen, Germany
Achilleas Gikas, Heraklion, Creta, Greece
Ferry Hagen, Nijmegen, Netherlands
Surbhi Malhotra-Kumar, Antwerp, Belgium
Alejandro Martin-Quiros, Madrid, Spain
Polona Maver Vodicar, Ljubljana, Slovenia
Malgorzata Mikulska, Genoa, Italy
Carlos Palos, Loures, Portugal
Hilpi Rautelin, Uppsala, Sweden
Jean-Paul Stahl, Grenoble, France
Matthias Willmann, Tübingen, Germany

Parity Commission (PC)

Maurizio Sanguinetti, Rome, Italy, *Chairperson*
Angela Huttner, Geneva, Switzerland
Alexandra Mailles, Saint-Maurice, France
Chrysanthi Skevaki, Marburg, Germany

Introduction to the Scientific Programme

Educational Workshops (EW)
Educational Workshops are organized in cooperation with ESCMID study groups and partnering organizations. They contain review talks and/or case studies that lend themselves to discussions. The goal of this format is education through interactivity. For the first time this year, these sessions are spread over the entire duration of the congress. Participants will be able to submit questions to speakers/chairs before the congress via *www.eccmidlive.org*.

Meet-the-Expert Sessions (ME)
Sunday through Tuesday, the day will start with Meet-the-Expert sessions led by recognized authorities in their fields. After a short presentation the experts will open the session for discussion, which will be driven by active audience participation. Participants will be able to submit questions to speakers before the congress via *www.eccmidlive.org*.

TAE Trainees Day (TD)
On **Saturday, 21 April 2018, 13.15 – 16.00** the Trainee Association of ESCMID (TAE) will organize the Trainees Day, a session dedicated to the unique needs of trainees. A main and popular part of the session is the round tables, which give younger professionals the chance to talk to experts in an informal setting. Participants can sign up for one of the 14 expert tables of their choice to talk about their career. This session will take place in **Hall Y.**

Keynote and Award Lectures (KN)
Renowned experts will share their expertise in their keynote lectures of 60 minutes.

Symposia (SY)
These symposia convene renowned speakers from all over the world and cover a wide range of topics in the fields of clinical microbiology, infectious diseases and infection control. A number of symposia are arranged in cooperation with ESCMID study groups, while others are jointly organized with partnering societies or organizations. Some of the symposia give an overview over recent developments and research results, while others review the literature or are presented as pro-con debates.
Symposia arranged by the industry are organized in close cooperation with the ECCMID Programme Committee. For details please see the Integrated Symposia and Exhibition Guide.

Oral Sessions (OS, OF, OE)
The programme features four types of oral presentation sessions:
(I) one-hour (five speakers; 12 minutes per speaker including discussion) and
(II) two-hour (ten speakers; 12 minutes per speaker including discussion).

These sessions are put together by the programme committee from the top-rated abstracts. This is the highest category of an abstract presentation. These sessions are chaired by two experts on the topic.

(III) In one-hour mini-oral flash sessions (12 speakers; five minutes per speaker including discussion) each speaker can present a maximum of three slides.
(IV) Mini-oral ePoster Sessions are held as one-hour sessions (nine speakers; six minutes per speaker including discussion) on ePoster terminals. These sessions are moderated by an expert.

All ePosters are displayed on all congress days on all ePoster terminals as well as in ESCMID's eLibrary. The presenting author is indicated by an asterisk (*).

Paper Poster Sessions (PS)
Most of the accepted abstracts are presented in paper poster sessions. The selection is based on a blind review by at least three experts. The paper posters are displayed in the poster area of the congress. The poster area is open to all participants. Please note that posters are exchanged on a daily basis. Poster authors must be present at their posters for discussion during their poster session (see page 112 for details). The presenting author is indicated by an asterisk (*). Paper posters, which have been shared electronically by the author(s), are shown on all four congress days on all ePoster terminals as well as in ESCMID's eLibrary.

ePoster Viewing (EV)
ePosters and electronic versions of the paper posters – if delivered by the author – will be displayed on all four congress days on all ePoster stations, on the mobile website and application of the congress and in ESCMID's eLibrary. The ePoster format will give participants the possibility to interact with presenters and send the ePoster (see page 260) by email. The presenting author is indicated by an asterisk (*).

The following prefixes have been used throughout the programme:

- EW = Educational Workshop
- ME = Meet-the-Expert Session
- TD = TAE Trainees Day 2018
- KN = Keynote Lecture
- SY = Symposium
- IS = Integrated Symposium (see industry book)
- OS = Oral Session
- OE = ePoster Mini-Oral Session
- PS = Paper Poster Session
- EV = ePoster Viewing
- OF = Mini-oral Flash Session
- OL = Mini-oral ePoster Session

Sessions specifically interesting for:

- (10) Infectious Disease Fellows
- (CM) Clinical Microbiologists
- (IC) Infection Control Practitioners

Scientific Programme
Saturday, 21 April 2018

ID

SY001 **08:45 – 10:45** **Hall H**
2-Hour Symposium

Why antibiotics fail in chronic infection therapy?

Chairs *Mark Everett Shirtliff (Baltimore, United States), Gianfranco Donelli (Rome, Italy)*

S0001 **08:45** **Biofilms in bone and joint infections: state-of-the-art**
Oana Ciofu (Copenhagen, Denmark)

S0002 **09:15** **Resistance and adaptation in chronic infections**
Helle Krogh Johansen (Copenhagen, Denmark)

S0003 **09:45** **'omic analyses of antimicrobial resistance and tolerance**
Susanne Häussler (Hannover, Germany)

S0004 **10:15** **Putting tolerance in its place - practical treatment guidelines**
Tom Coenye (Ghent, Belgium)

ID

SY002 **08:45 – 10:45** **Hall I**
2-Hour Symposium

Infections and biologicals: a real concern?

Chairs *Jose Maria Aguado Garcia (Madrid, Spain), Malgorzata Mikulska (Genoa, Italy)*

S0005 **08:45** **New biological therapies: introduction to the basis of the risk for infection**
Mario Fernandez Ruiz (Madrid, Spain)

S0006 **09:15** **Current risk of anti-TNF drugs**
John Baddley (Birmingham, United States)

S0007 **09:45** **Tyrosine kinase inhibitors: a threat?**
Mark Reinwald (Brandenburg an der Havel, Germany)

S0008 **10:15** **Immunotherapy (T-cell checkpoint blockade): what to expect?**
Dimitrios P. Kontoyiannis (Houston, United States)

Co-organized with: ESGICH - ESCMID SG for Infections in Compromised Hosts

SY003 **08:45 – 10:45** **Hall J**
2-Hour Symposium

Arboviruses: resurgence of a past neglected problem

Chairs *Guido Antonelli, Rome, Italy*
Anna Papa, Thessaloniki, Greece

S0009 **08:45** **New anti-mosquito and larvicidal agents in the lab and in the field**
Raquel M. Gleiser (Cordoba, Argentina)

S0010 **09:15** **Risk of yellow fever urbanization in endemic areas of dengue**
Marcelo N. Burattini (São Paulo, Brazil)

S0011 **09:45** **Congenital Zika virus infection: insights from studies of pregnant macaques**
Matthew T. Aliota (Madison, United States)

S0012 **10:15** **New perspectives of novel Zika and dengue vaccines**
Jorge Elias Kalil Filho (São Paulo, Brazil)

CM

EW004 **08:45 – 12:45** **Hall A**
4-hour Educational Workshop

Antimicrobial susceptibility testing with EUCAST breakpoints and methods

Chairs *Arjana Tambic Andrasevic (Zagreb, Croatia), Alasdair P. MacGowan (Bristol, United Kingdom)*

W0013 **08:45** **What is new in EUCAST?**
Christian G. Giske (Stockholm, Sweden)

W0014 **09:15** **Carbapenem and aminoglycoside breakpoints revisited**
Johan Willem Mouton (Rotterdam, Netherlands)

W0015 **09:45** **Expert rules - finally there**
Sören G. Gatermann (Bochum, Germany)

W0016 **10:15** **Standardisation of antimicrobial susceptibility testing of *M. tuberculosis***
Emmanuelle Cambau (Paris, France)

W0017 **10:45** **Rapid AST with disk diffusion on direct inoculation from blood culture bottles**
Gunnar Kahlmeter (Växjö, Sweden)

W0018 **11:15** **Implementing breakpoints outside Europe**
John D. Turnidge (Mitcham, Australia)

W0019 **11:45** **Susceptibility testing of anaerobic bacteria**
Ulrik Stenz Justesen (Odense, Denmark)

Co-organized with: European Committee on Antimicrobial Susceptibility Testing (EUCAST)

IC

EW005 **08:45 – 12:30** **Hall D**
4-hour Educational Workshop

Hands-on infection control - what does actually work to prevent infections?

Chairs *Jean-Christophe Lucet (Paris, France), Elisabeth Presterl (Vienna, Austria)*

W0020 **08:45** **The standard of care for infection control in 2018**
Loreen Herwaldt (Iowa City, United States)

W0021 **09:05** **Before an outbreak - surveillance, data management and alerts in infection control**
Eli Perencevich (Iowa City, United States)

W0022 **09:25** **Before an outbreak - what to do after first MDR Gram-negatives enter your hospital?**
Jonathan Otter (London, United Kingdom)

W0023 **09:45** **Before an outbreak - is complete sanitation of robotic surgical instruments possible?**
Petra Gastmeier (Berlin, Germany)

P1666 **Outer mebrane protein targeting antibiotics (OMPTAs): a novel class with potent *in vitro* and *in vivo* activity against *E. coli*-harbouring *mcr-1* and/or *mcr-3* genes**
G. Dale (Allschwil, Switzerland), J. Teague, C. Vingsbo Lundberg, A. Luther, F. Bernardini, D. Obrecht*

P1667 **Investigation of the *in vitro* time-kill kinetics and the rate of resistance development by spontaneous mutations and serial passage of murepavadin and standard-of-care antibiotics towards *P. aeruginosa***
F. Bernardini (Allschwil, Switzerland), P. Chiquet, C. Verbree, S. Stiegeler, G. Dale*

P1668 **Outer membrane protein targeting antibiotics (OMPTAs): investigation of the *in vitro* time-kill kinetics and rate of resistance development by serial passage**
F. Bernardini (Allschwil, Switzerland), C. Verbree, S. Stiegeler, P. Chiquet, G. Dale*

P1669 **Ceragenins exhibiting significant antimicrobial potential against various colistin-resistant Gram-negative bacteria**
Ö. Oyardi, M. Hacioglu (Istanbul, Turkey), P. Savage, A. Akcali, C. Bozkurt Guzel*

P1670 **Antimicrobial activity evaluation of newly designed antimicrobial peptides against multidrug-resistant bacteria.**
J. Moreno Morales (Barcelona, Spain), D. Kalafatovic, C. Ballesté, E. Giralt, J. Vila Estape*

PS084 13:30 - 14:30

Seeking synergy in drug combinations

P1671 **Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infections**
R. Mendes (North Liberty, United States), P. Rhomberg, T. Lister, N. Cotroneo, A. Rubio, R. Flamm*

P1672 **Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenging set of Gram-negative pathogens**
R. Mendes (North Liberty, United States), P. Rhomberg, T. Lister, N. Cotroneo, A. Rubio, R. Flamm*

P1673 ***In vitro* activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria**
D. Citron, K. Tyrrell, A. Rubio (Cambridge, United States), E. Goldstein*

P1674 **Bactericidal activity of ceftazidime in combination with SPR741 against susceptible, extended-spectrum beta-lactamase producing, and multi-drug resistant *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* species**
Y. Zou, N. Cotroneo (Westford, United States), T. Lister, A. Rubio*

P1675 **Bactericidal activity of piperacillin-tazobactam in combination with SPR741 against susceptible, extended-spectrum beta-lactamase producing, and multidrug-resistant *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* species**
Y. Zou, N. Cotroneo (Westford, United States), T. Lister, A. Rubio*

P1676 **Should caffeic acid phenethyl ester be added to colistin for the treatment of *Acinetobacter baumannii* mediastinitis: experimental rat model**
M. Yetkin (Giresun, Turkey), O. Keskin, I. Yavuz, N. Cebeci Güler*

P1677 **Hydrazone-based transition metal complexes as novel antiviral agents and antibiotic adjuvants: an *in vitro* study**
G. Spengler (Szeged, Hungary), M. Gajdács, A. Kincses, M. Nové, B. Barta Holló, T. Mosolygó, K. Burian, K. Mészáros Szécsényi*

P1678 ***In vitro* and *in vivo* activity of the manganese carbonyl complex *[Mn(CO)3(bqpa-k3N)]Br* alone and in combination with polymyxin B against multidrug-resistant clinical isolates of *Acinetobacteri baumannii***
J. Betts (Guildford, United Kingdom), R. La Ragione, U. Schatzschneider, R. Poole*

P1679 **Resensitizing the antibiotic aztreonam using the polyphenol epigallocatechin gallate against multidrug-resistant clinical isolates of *Pseudomonas aeruginosa* and *Acinetobacter baumannii***
J. Betts (Guildford, United Kingdom), M. Hornsey, P. Higgins, H. Seifert, R. La Ragione*

P1680 **Evaluation of meropenem plus tobramycin combination regimens to combat carbapenem nonsusceptible *Pseudomonas aeruginosa* for critically-ill patients with augmented renal clearance via the hollow-fibre infection model and mechanism-based modelling**
R. Yadav, P. Bergen, K. Rogers, C. Kirkpatrick, S. Wallis, J. Bulitta, D. Paterson, R. Nation, J. Lipman, J. Roberts, C. Landersdorfer (Parkville, Australia)*

28th ECCMID EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
Madrid, Spain
21 – 24 April 2018

P1669 Ceragenins exhibiting significant antimicrobial potential against various colistin-resistant Gram-negative bacteria

Özlem Oyardı[2], Mayram Hacioglu*[2], Paul B. Savage[1], Alper Akcali[3], Cagla Bozkurt Guzel[2]

[1]Brigham Young University, Chemistry and biochemisty, [2]Istanbul university, Pharmaceutical microbiology, [3]Canakkale Onsekiz Mart University, School of Medicine, Medical Microbiology, Canakkale, Turkey

Background: Antibiotic resistant bacteria, especially gram-negative bacteria, cause an increased concern. Colistin is increasingly used by clinicians as only option to treat these infections. However, colistin resistance has been reported due to its widespread use in many countries. Therefore, there is a need for development new drugs to treat these infections. Ceragenins, which are cationic derivatives of colic acid, are ones of the new generation of promising agents in this regard. Ceragenins, Cationic Steroid Antibiotics (CSA), mimic the activities of natural antimicrobial peptides (AMPs) and target bacterial membranes. Thus, in this study, the effects of ceragenins against some colistin-resistant Gram-negative bacteria were determined.

Materials/methods: The antimicrobial activities of CSA-8, CSA-13, CSA-131, CSA-138, CSA-142 and CSA-192 were studied against 17 colistin-resistant strains including *Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* isolated from various specimens. A total of 17 clinically isolated strains collected in Hospital of Çanakkale Onsekiz Mart University in Turkey in 2016. Meropenem, gentamicin, colistin and levofloxacin also used in this study. MICs and MBCs were determined by microdilution method according to CLSI.

Results: Almost all of the microorganisms were also found resistant to colistin, meropenem, gentamicin and levofloxacin. Only two *K. pneumoniae* strains showed susceptibility to meropenem. According to the results, CSA-13 (MIC: 8-16 µg/ml), CSA-131 (MIC: 8 µg/ml) and CSA-138 (MIC: 8-16 µg/ml) were determined as the most effective agents. The least effective agent was CSA-8 (MIC: >128 µg/ml) against all microorganisms. CSA-44 (MIC: 8-64 µg/ml) and CSA-142 ((MIC: 8-64 µg/ml) showed moderate activity. Antibacterial activity of CSA-192 was determined 64->128 µg/ml. Among microorganisms, all CSAs showed the lowest activity against *M. morganii* (one strain). The MBCs were generally equal to or two fold greater than those of the MICs.

Conclusions: Consequently, multiple drug resistance was detected in all tested bacteria. Apparently, new agents are needed to treat the diseases caused by these bacteria. Our study showed that ceragenins, especially CSA-13, CSA-131 and CSA-138, are promising agents against colistin-resistant Gram-negative strains.

Carla Seiler <carla.seiler@escmid.org> 24 Oca 2018 Çar 18:26
Alıcı: ben

İngilizce Türkçe İletiyi çevir İngilizce için kapat

Basel, 24.01.2018

Dear Özlem Oyardı
Title: Ceragenins exhibiting significant antimicrobial potential against various colistin-resistant Gram-negative bacteria
Abstract number: 5286

Thank you very much for having submitted an abstract to ECCMID, 21 – 24 April 2018, Madrid, Spain. The response to the call was extremely high.
The ECCMID 2018 Programme Committee is pleased to inform you that the above-mentioned abstract has been accepted for ECCMID 2018. Session type: Paper Poster or ePoster viewing
The name of your session and the exact date and time will be communicated within the next two weeks.
If you are not the presenting author, please forward this notification to the presenting author and inform the Abstract Team at eccmidabstracts@escmid.org.
The final scientific programme will be available online on www.eccmid.org in early February 2018; however, the abstracts themselves, including abstract titles, will be released 11 April 2018.
If you have not yet registered for the meeting, please do so now online on the ECCMID website. Please note that abstracts without a registered presenting author will not be part of ECCMID 2018. The presenting author must register before 28 February 2018 to ensure publication of the abstract in the ESCMID eLibrary and on the congress website. If you are unable to attend please advise us of your withdrawal before 28 February 2018.
The early registration fee applies until 26 January 2018.
Again, we congratulate you on the acceptance of your abstract and are looking forward to seeing you in Madrid. If you have any questions or need assistance, please feel free to contact us at eccmidabstracts@escmid.org.

Yours sincerely,
ECCMID 2018 Abstract Team
On behalf of the ECCMID 2018 Programme Committee

28th ECCMID

...

[İleti kısaltıldı] Tüm iletiyi görüntüle